Key result
Nifedipine-retard did not significantly reduce the overall incidence of cardiac events compared to non-calcium channel blocker treatment in post-myocardial infarction patients (OR 0.584, p=0.14).
Why the study?
Does nifedipine-retard reduce the occurrence of cardiac death or non-fatal myocardial infarction in post-MI patients treated with coronary thrombolysis?
Population
294 Japanese patients who survived acute myocardial infarction and were discharged alive after receiving…
Comparison
Nifedipine-retard, mostly 40 mg/day divided into… vs Non-calcium channel blocker (non-CCB) treatment.
Design
Cohort
Follow-up
median 6.3+/-2.4 years
Authors
Loading...
Does not support nifedipine-retard for post-MI event reduction; leaves open possible benefits in younger non-smokers pending RCTs.
Cohort (n=294)
No
Does nifedipine-retard reduce the occurrence of cardiac death or non-fatal myocardial infarction in post-MI patients treated with coronary thrombolysis?
Odds Ratio: 0.584 (95% CI 0.286–1.193)
Absolute Event Rate: 8.9% vs 14.1%
p-value: p=0.14
Retrospective analysis suggests that sustained-release nifedipine does not increase cardiac events in post-MI patients and may offer secondary prevention benefits in younger patients (<55 years) and non-smokers.
Tani et al. (2004) conducted a cohort in Acute myocardial infarction (secondary prevention) (n=294). Nifedipine-retard vs. Non-calcium channel blockers was evaluated on Occurrence of cardiac death or non-fatal myocardial infarction (OR 0.584, 95% CI 0.286-1.193, p=0.14). Nifedipine-retard did not significantly reduce the overall incidence of cardiac events compared to non-calcium channel blocker treatment in post-myocardial infarction patients (OR 0.584, p=0.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: